# The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma

> **NCT04769076** · PHASE2 · UNKNOWN · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 40 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **COMBINATION_PRODUCT:** Paclitaxel（Albumin-bound）

## Key facts

- **NCT ID:** NCT04769076
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-01
- **Primary completion:** 2025-12-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2021-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04769076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04769076, "The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04769076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*